Rallybio Corp — Form 8-K

Jonathan Lieber, CFO and Treasurer since February 2023, transitions to part-time employment effective September 8–15, 2026, with annualized base salary reduced to $420,000 (from prior full-time rate, unspecified), forfeits all annual bonuses, and employment terminates at the closing of Rallybio's pending merger with Avenzo Therapeutics (Merger Agreement dated May 31, 2026). Upon termination at Closing, Lieber receives severance and benefits for termination without Cause in a Change in Control per his Employment Agreement Section 7(d); if terminated without Cause before Closing, he receives Section 7(c) severance, upgraded to Section 7(d) if the merger closes thereafter. His equity awards remain outstanding and eligible to vest per merger terms; vested stock options exercisable for 90 days post-Closing.